Influenza Clinical Trial
Official title:
A Phase 2b Double-blind, Randomized, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of Norketotifen (NKT) in the Treatment of Acute Uncomplicated Influenza-like Illness (ILI)
Verified date | January 2023 |
Source | Emergo Therapeutics, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase 2b, multi-center, double-blind, randomized, placebo-controlled, parallel-group study of NKT versus placebo in otherwise healthy adults presenting with acute uncomplicated ILI due to influenza or other respiratory viruses in a community setting.
Status | Completed |
Enrollment | 315 |
Est. completion date | February 9, 2022 |
Est. primary completion date | January 25, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 64 Years |
Eligibility | Inclusion Criteria: 1. Able to understand the study and comply with all study procedures, and willing to provide written informed consent prior to the pre-dose examinations 2. Symptoms of ILI including all of the following: - Fever =38º Celsius (oral) - At least one of the following general systemic symptoms associated with ILI are present with a severity of moderate or greater: headache, feverishness or chills, muscle or joint pain, fatigue - At least one of the following respiratory symptoms associated with ILI are present with a severity of moderate or greater: cough, sore throat, nasal congestion 3. Total symptom severity score (sum of the scores of all 7 individual symptoms) of =11 in the predose examinations 4. The time interval between the onset of symptoms and the predose examinations is =48 hours. 5. Females of childbearing potential and males agree to use an appropriate method of contraception as detailed in the protocol Exclusion Criteria: 1. Known or suspected infection with Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV2) or Coronavirus Disease 2019 (COVID-19) illness 2. Female subjects who are pregnant, 2 weeks post-partum, or breastfeeding 3. Severe ILI requiring inpatient treatment 4. Any of the following risk factors (according to the CDC's list of People at High Risk for Developing Serious Flu-Related Complications): - Extreme obesity (body mass index =40 kg/m^2) - Residents of nursing homes or other long-term care facilities - American Indians and Alaska natives - Asthma - Chronic lung disease (such as chronic obstructive pulmonary disease or cystic fibrosis) - Neurological and neurodevelopmental conditions (including disorders of the brain, spinal cord, peripheral nerve, and muscle such as cerebral palsy, epilepsy [seizure disorders], stroke, intellectual disability, moderate to severe developmental delay, muscular dystrophy, or spinal cord injury) - Heart disease (such as congenital heart disease, congestive heart failure, or coronary artery disease) - Blood disorders (such as sickle cell disease) - Endocrine disorders (such as diabetes mellitus) - Kidney disorders - Liver disorders - Metabolic disorders (such as inherited metabolic disorders and mitochondrial disorders) - Compromised immune system due to disease or medication (such as subjects with human immunodeficiency virus or cancer, or those on chronic steroids) 5. Presence of any severe or uncontrolled medical or psychiatric illness 6. History of or current autoimmune disease 7. History of recurrent lower respiratory tract infection 8. Any concurrent infection requiring systemic antimicrobial and/or antiviral therapy 9. Any clinically significant electrocardiogram (ECG) test 10. Received baloxavir, oseltamivir, peramivir, zanamivir, rimantadine, or amantadine within 30 days prior to the predose examinations 11. Received an investigational monoclonal antibody for a viral disease in the last year prior to the predose examinations 12. Received ketotifen fumarate, cromolyn sodium, or nedocromil sodium by any route of administration within 30 days prior to the predose examinations 13. Exposure to an investigational drug within 30 days prior to the predose examinations 14. History of allergic reaction to ketotifen 15. Any prior exposure to norketotifen |
Country | Name | City | State |
---|---|---|---|
United States | Cedar Health Research | Dallas | Texas |
United States | Omega Research Debary | DeBary | Florida |
United States | Horizon Research Group of Opelousas | Eunice | Louisiana |
United States | Advanced Medical Group | Houston | Texas |
United States | Clinical Research Solutions | Jackson | Tennessee |
United States | The Chappel Group Research | Kissimmee | Florida |
United States | Clinical Research of South Nevada | Las Vegas | Nevada |
United States | Downtown LA Research Center | Los Angeles | California |
United States | Relief Integrated Health Care | Louisburg | North Carolina |
United States | Premier Research Associate | Miami | Florida |
United States | Research Institute of South Florida | Miami | Florida |
United States | South Florida Research Center | Miami | Florida |
United States | Clinical Research Solutions | Middleburg Heights | Ohio |
United States | Frontier Clinical Research | Morgantown | West Virginia |
United States | Precision Trials AZ | Phoenix | Arizona |
United States | Health Concepts | Rapid City | South Dakota |
United States | Frontier Clinical Research | Scottdale | Pennsylvania |
United States | Frontier Clinical Research | Smithfield | Pennsylvania |
United States | Continental Clinical Solutions | Towson | Maryland |
United States | Clinovacare Medical Research Center | West Columbia | South Carolina |
Lead Sponsor | Collaborator |
---|---|
Emergo Therapeutics, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to alleviation of symptoms | Time to alleviation of the symptoms of ILI (headache, feverishness/chills, muscle/joint pain, fatigue, cough, sore throat, nasal congestion) | 14 days | |
Secondary | Time to resolution of fever (body temperature equal to or less than 37ºC) | 14 days | ||
Secondary | Proportion of subjects whose symptoms have been alleviated at each time point through Day 14 | 14 days | ||
Secondary | Change from baseline in composite symptom score at each time point through Day 14 | 14 days | ||
Secondary | Body temperature at each time point through Day 14 | 14 days | ||
Secondary | Time to alleviation of individual symptoms (headache, feverishness/chills, muscle/joint pain, fatigue, cough, sore throat, nasal congestion) | 14 days | ||
Secondary | Time to resumption of normal activity | 14 days | ||
Secondary | Use of rescue medication (acetaminophen) | 14 days | ||
Secondary | Time to alleviation of symptoms by confirmed viral pathogen (influenza vs non influenza) | 14 days | ||
Secondary | Time to resolution of fever by confirmed viral pathogen (influenza vs non influenza) | 14 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |